Cancer is a disease of striking significance in the world today. It represents the second leading cause of human mortality after cardiovascular diseases. In order to develop more effective and reliable anticancer agents, a large number of compounds bearing nitrogen-containing fused heterocyclic skeletons, such as 4-anilinoquinazolines, pyrazolopyrimidines, triazolopyrimidines, pyrrolopyrimidines, pyrazolopyridazines and imidazopyrazines, have been discovered particularly and many of them exhibited excellent anticancer activity. [1] [2] [3] [4] [5] Recently, [1, 2, 4] triazolo [1,5-a]pyrimidines have aroused increasing attentions from chemical and biological view points since they were proved to be the promising anticancer agents with a unique mechanism of promoting tubulin polymerization 1, 6) as well as the mechanism of cyclin-dependent kinases-2 inhibition.
Cancer is a disease of striking significance in the world today. It represents the second leading cause of human mortality after cardiovascular diseases. In order to develop more effective and reliable anticancer agents, a large number of compounds bearing nitrogen-containing fused heterocyclic skeletons, such as 4-anilinoquinazolines, pyrazolopyrimidines, triazolopyrimidines, pyrrolopyrimidines, pyrazolopyridazines and imidazopyrazines, have been discovered particularly and many of them exhibited excellent anticancer activity. [1] [2] [3] [4] [5] Recently, [1, 2, 4] triazolo [1,5-a] pyrimidines have aroused increasing attentions from chemical and biological view points since they were proved to be the promising anticancer agents with a unique mechanism of promoting tubulin polymerization 1, 6) as well as the mechanism of cyclin-dependent kinases-2 inhibition. 7) It was not until recently that some N-anilino- [1, 2, 4] triazolo [1,5-a] pyrimidine-7-amine analogs bearing functional groups at C-2 position were reported for their good cytotoxicity, 8, 9) which have largely inspired us and directed parallel developments in the chemistry and cytotoxicity studies of these related derivatives. 10) With an aim to produce [1, 2, 4] triazolo [1,5-a] pyrimidine-7-amine derivatives endowed with improved solubility and better biological interactions, a series of new molecules containing nitrogen atoms in the terminal of side chain at C-2 position on the scaffold were designed and synthesized. Further modifications were performed by introducing various alkylaminomethyl functional groups into C-5 position of furan ring in the side chain and substituted anilines into C-7 position in the [1, 2, 4] triazolo [1,5-a] pyrimidine core.
In this paper, we would like to report the synthesis and cytotoxicity of a series of novel N-anilino-5-methyl-2-(3-(5-(alkylaminomethyl)furan-2-yl-methylthio)propyl)- [1, 2, 4] triazolo [1,5-a] pyrimidine-7-amines represented by the general structure of 7-24 in Fig. 1 .
Results and Discussion
Chemistry The title [1, 2, 4] triazolo [1,5-a] pyrimidine-7-amine derivatives 7-24 were synthesized as shown in Chart 1. Commercially available g-butyrolactone was treated with aminoguanidine carbonate in pyridine to give the 5-amino-3-(3-hydroxypropyl)-4H-[1,2,4]-triazole 2 in 40% yield exclusively. As described in literature, 11) cyclization of 2 with ethyl acetoacetate was carried out in acetic acid at reflux to afford the 3Ј-hydroxy acetylized intermediate, which was converted to hydroxylate 3 by further reaction with ammonia in methanol in 88% yield. Subsequent treatment of 3 with excess phosphorus oxychloride afforded chloro derivative 4, a key synthon for further elaboration, in 94% yield. Coupling reaction of 4 with various anilines provided the intermediates 5a-d in 87-93% yields after recrystallization. By etherification of 5a-d with (furan-2-yl)methanethiol in the presence of an excess amount of sodium hydride in dried DMF, the key intermediates 6a-d were obtained.
To further investigate the influence on cytotoxicity of polar chains that facilitate the solubility and the biological interactions, we introduced various Mannich bases into the C-5 position of furan ring in the side chain by reaction of compounds 6a-d with appropriate secondary amines and formaldehyde, followed by column chromatographic purification to afford the desired compounds 7-24 in 45-80% yields.
Cytotoxicity and Discussion Cytotoxicity of the synthesized compounds 7-24 against Bel-7402 (Human Liver Cancer) and HT-1080 (Human Fibro Sarcoma) cell lines were determined by MTT assay. Cisplatin as positive control, and the results expressed as IC 50 are summarized in Table 1 .
As shown in Table 1 , most of the evaluated compounds exhibited good cytotoxicity, and compounds 9, 14, 19 and 23, bearing pyrrolidinylmethyl groups at C-5 position on furyl moieties, possessed even better in vitro cytotoxicity against both two tumor cell lines than cisplatin. Among all the tested compounds, 23 was of particular interest because of its marked activity (IC 50 values of 15.0 mM and 7.8 mM against Bel-7402 and HT-1080 cell lines, respectively) and had emerged as lead compound.
Synthesis and Cytotoxicity Studies of Novel [1,2,4]Triazolo[1,5-a]pyrimidine-7-amines
The data indicated that 3-(5-(alkylaminomethyl)ffuran-2-yl-methylthio)propyl side chain at C-2 position on [1,2,4]triazolo[1,5-a]pyrimidine scaffold had a very important effect on anti-tumor activity, and variations of the terminal substituents at C-5 position of furan ring would change the activity dramatically. Generally, pyrrolidinyl was the most potent substituent which produced the compounds with excellent activity, as demonstrated by 9, 14, 19 and 23. In addition, piperidinyl and dimethylamino also had good contributions to the anti-tumor activity, while morpholinyl and 4-methylpiperizinyl resulted in dramatic decrease or abolishment in anti-tumor potency. A case in point is that compound 17 with morpholinylmethyl group at C-5 position of furan ring almost abolished the activity, whereas 19 bearing pyrrolidinylmethyl substituent provided a 2-fold increase in potency against two tumor cell lines relative to the positive control. On the other hands, 4-triflouromethylanilino substituent at C-7 position on the skeleton was an option for anticancer potency, as 21-24 showed more potent cytotoxicity superior to the corresponding compounds bearing 3-chloroanilino, 3-chloro-4-fluoroanilino and 4-trifluoromethoxyanilino substituents at C-7 position. Furthermore, all of the compounds, except for 12 and 21, were more potent on the HT-1080 cells than on the Bel-7402 cells (about 2-fold in the case of 9, 10, 14, 16, 19, 20, 23).
Conclusion
We reported the synthesis and evaluation of cytotoxic activity of novel [1, 2, 4] triazolo[1,5-a]pyrimidine-7-amine derivatives. Among the tested compounds, 23 is considered promising lead for further structural modifications. The activity was found to depend strongly on substitution pattern of the side chains at C-2 position, so eventually the activity of the compounds could be tailored by further structural modifications. The results of this study will provide useful information for the design of novel molecules as cytotoxic agents.
Experimental
Melting points were determined by the capillary tube method and were uncorrected. Infrared spectra were obtained from KBr pellets on a Bruker IFS 55 instrument. 1 H-NMR spectra were recorded at 300 MHz on a Bruker ARX-300 instrument and chemical shifts are reported in parts per million (d) downfield from TMS as the internal standard. Mass spectra were carrided out with an Agilent 1100 HPLC-MS instrument. Elemental analyses were performed with a Carlo-Erba 1106 analyzer. All reagents and solvents were commercially available unless otherwise indicated.
5-Amino-3-(3-hydroxypropyl)-4H-[1,2,4]triazole (2)
A mixture of aminoguanidine (65 g, 0.55 mol) and g-butyrolactone (43 g, 0.50 mol) in pyridine (900 ml) was stirred for 10 h at reflux. The solvent was evaporated under vacuum and the resultant mixture was filtered to give a pale solid. The mass product was recrystallized from absolute ethanol (150 ml) and dried to give 28 g (40%) of 2 as a white solid, mp 147-148°C (lit. 149-150°C 12) ). 24 mol) in acetic acid (300 ml) was stirred for 30 h at reflux. Acetic acid was evaporated under vacuum and the resultant mixture was filtered. The resulting off-white solid was then added into the saturated ammonia methanol (300 ml) and stirred at room temperature for 24 h. The mixture was evaporated and water (400 ml) was added, which was then acidified with dilute hy- 
7-Chloro-2-(3-chloropropyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidine (4)
A mixture of 3 (37 g, 0.18 mol) and phosphorus oxychloride (265 g, 1.70 mol) was heated to reflux for 3 h, and then was concentrated in vacuum to result a red oil, which was poured into water, and extracted with chloroform (250 mlϫ3). The organic layer was then washed with water three times, dried with anhydrous magnesium sulfate and concentrated to give 4 (41 g, 94%) as a yellow solid (LC purity: 96%, MS m/z: 245.2 (M ϩ )), which was directly used in next step without purification.
General 
General Procedure for the Preparation of N-Anilino-2-(3-(ffuran-2-ylmethylthio)propyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amines
Furan-2-ylmethanethiol (8.6 g, 75 mmol) was added dropwise into a suspension of NaH (1.8 g 75 mmol) in dried DMF (80 ml) at room temperature. After the addition, the mixture was stirred for 5 min, and then 5a-d (25 mmol) was added in one portion. The mixture was heated at 50°C for 30 min and then poured into water. The brown oil which separated from water was triturated with diethyl ether. The resulting precipitate was collected by filtration, washed well with water and further purified by recrystallization from ethyl acetate/cyclohexane to afford 6a-d as gray solid (80-85%). NH, 13 mmol). The mixture was stirred at 30°C for 10 min, and then 6a-d (5 mmol) was added. After stirring at 50°C for 4 h, the mixture was concentrated in vacuum. The residue was treated with water (50 ml), basified with concentrated aqueous sodium hydroxide to pH 9-10, extracted with methylene dichloride, and then dried over magnesium sulfate. Evaporation of the solvent provided an oil residue, which was purified by column chromatography to give the final products 7-24 as off-white powder.
N-(3-Chlorophenyl)-5-methyl-2-(3-((5-(morpholinomethyl)furan-2-yl)methylthio)propyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (7)
Prepared from 6a and morpholine, 73% yield. mp 170-172°C. 
N-(3-Chlorophenyl)-5-methyl-2-(3-((5-(piperidin-1-ylmethyl)furan-2-yl)methylthio)propyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine (8)
Prepared from 6a and piperidine, 65% yield. mp 166-168°C. ((4-methylpiperazin-1-yl)methyl)furan-2-yl)methylthio)propyl)-[1,2,4]triazolo[1,5-a] N-(3-Chlorophenyl)-2-(3-((5-((dimethylamino)methyl)furan-2-yl)methylthio)propyl)-5-methyl-[1,2,4]triazolo[1,5-a] (piperidin-1-ylmethyl)furan-2-yl)methylthio)-propyl)-N-(4-(trifluoromethoxy)phenyl)-[1,2,4]triazolo[1,5-a] N-(4-(trifluoromethoxy)phenyl)-[1,2,4]triazolo[1,5-a] 5-((4-methylpiperazin-1-yl)methyl)furan-2-yl)-methylthio)propyl)-N-(4-(trifluoromethoxy)phenyl)-[1,2,4 Approximately 4ϫ10 3 cells, suspended in MEM medium, were plated onto each well of a 96-well plate and incubated in 5% CO 2 at 37°C for 24 h. The test compounds at indicated final concentrations were added to the culture medium and the cell cultures were continued for 72 h. Fresh MTT was added to each well at a terminal concentration of 5 mg/ml and incubated with cells at 37°C for 4 h. The formazan crystals were dissolved in 100 ml DMSO each well, and the absorbency at 492 nm (for absorbance of MTT formazan) and 630 nm (for the reference wavelength) was measured with the ELISA reader.
The cytotoxicity effect was expressed as the IC 50 , which was calculated by Bliss.
